Higher sales, improved margins and launches with high customer value

Handelsbanken Life Science Innovation Day

August 2024




Key takeaways

Q2 2024

- Net sales increased by 15.7% whereof 8.9% organically and order intake grew by 14.4% whereof 7.8% organically
- Margins positively impacted by volume, product mix and price realizations
- The financial position remains solid









Key activities and events

Q2 2024

Offering and customers

- Launched Poladus 150, an advanced low-temperature sterilizer
- 510(k) clearance for Talis Advanced
 Clinical Guidance
- Advanta V12 was approved according to EU MDR
- Launched the GEW888 neo washer
- A new version of DPTE-BetaBag®

Updated financial target

 Average annual growth in adjusted EPS: >12% 2024-2028

Sustainability and Quality

- Accelerated the remediation efforts and the plan for the next generation of Cardiosave balloon pump and Cardiohelp ECLS system
- Submitted application for CE mark of new packaging for HLS and PLS sets



Getinge Poladus 150, low temperature sterilizer




Organic sales growth in all regions thanks to Acute Care Therapies

Soft organic order intake in Americas due to Surgical Workflows and Life Science

Global


+7.8%
Organic Order Growth

+8.9%
Organic Net Sales Growth



Outlook 2024


Net sales for 2024 expected to increase by 2-5% organically (unchanged)





Organic order growth in all business areas


Order Intake Bridge Q2 2023 – Q2 2024





Strong sales growth in Acute Care Therapies vs last year's low comps


Net Sales Bridge Q2 2023 – Q2 2024





Adj Gross Margin increased in all business areas versus last year


Adjusted Gross Profit Bridge Q2 2023 – Q2 2024





Adj EBITA margin increased versus last year's low comp


Adjusted EBITA Bridge Q2 2023 – Q2 2024





Stable Free Cash Flow and Working Capital days trending down

Capital efficiency a priority



Free Cash Flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations

Working Capital, as defined on this page, is including accounts receivables, accounts payables and inventory - adjusted for currency

Operating ROIC: Trailing 12 month adjusted EBIT/Invested Capital. Invested capital is defined as Equity + Net debt (excl. pension liabilities) and calculated as (Opening balance + Closing balance of Invested Capital)/2




Solid financial position

Recent acquisitions impacting net debt, but financial position is strong

Net debt increased due to acquisitions ...

... but leverage is way below 2.5x





Summary



Key takeaways

Summary Q2 2024

- Strong growth in net sales and orders
- Improved margins
- Solid financial position



Thank you



Forward looking information

This document contains forward-looking information based on the current expectations of the Getinge's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.





PASSION FOR LIFE